UMIN-CTR Clinical Trial

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000021699
Receipt No. R000025036
Official scientific title of the study Clinical Features, Medical Costs and Radiographic Resolution of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.
Date of disclosure of the study information 2016/03/31
Last modified on 2016/04/05 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Clinical Features, Medical Costs and Radiographic Resolution of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.
Title of the study (Brief title) Clinical Features, Medical Costs and Radiographic Resolution of CAP in Patients with COPD
Region
Japan

Condition
Condition chronic obstructive pulmonary disease (COPD), Community-acquired pneumonia (CAP)
Classification by specialty
Medicine in general Pneumology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the clinical features and radiographic changes of CAP in patients with COPD. We also aimed to assertion the duration of radiographic clearance of proven CAP in COPD patients
Basic objectives2 Others
Basic objectives -Others
Trial characteristics_1 Others
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes The rate of radiographic clearance of CAP
Key secondary outcomes Clinical Features of CAP, Medical Cost

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit
30 years-old <=
Age-upper limit
90 years-old >=
Gender Male and Female
Key inclusion criteria Pneumonia patients diagnosed as CAP
Clinically stable patients with moderate to severe COPD,who are 30 years of age or older and have smoking history or current smokers and stop smoking at the time of giving the consent to this study..
They all provide written, informed consent.
Key exclusion criteria Exclusion criteria: (1) Coexistence of other major pulmonary diseases such as asthma, bronchiectasis, pulmonary fibrosis, tuberculosis, and pulmonary cancer diagnosed by imaging modalities and/or laboratory findings. Asthma is excluded based on clinical history and/or laboratory findings, including levels of IgE and/or eosinophils in blood and/or sputum, but not based on reversibility of airflow limitation.
(2)patients with cancers
(3)patients with other serious complocations
(4) Those who are considered as inappropriate subjects for any reasons.
Target sample size 200

Research contact person
Name of lead principal investigator Shinji Teramoto
Organization Hitachinaka General Hospital
Division name Department of pulmonary medicine
Address 20-1 Ishikawa-cho, Hitachinaka-shi, Ibaraki,Japan 312-0057
TEL 029-354-5111
Email shinjit-tky@umin.ac.jp

Public contact
Name of contact person Shinji Teramoto
Organization Hitachinaka General Hospital
Division name Department of pulmonary medicine
Address 20-1 Ishikawa-cho Hitachinaka-shi
TEL 029-354-5111
Homepage URL
Email shinjit-tky@umin.ac.jp

Sponsor
Institute Hitachinaka General Hospital
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and
report of the research including funding management. It doesn't mean
funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization Hitachinaka General Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 03 Month 31 Day

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2013 Year 03 Month 29 Day
Anticipated trial start date
2014 Year 04 Month 01 Day
Last follow-up date
2016 Year 03 Month 29 Day
Date of closure to data entry
2016 Year 03 Month 29 Day
Date trial data considered complete
2016 Year 03 Month 29 Day
Date analysis concluded
2016 Year 08 Month 29 Day

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information An observational analysis of a prospective cohort of hospitalized adults with CAP (from 2014 to 2016) is performed. Chest radiographs are performed every weeks from the date of admission for a total period of 16 weeks or until all radiographic abnormalities had resolved or returned to baseline. The medical cost for CAP was compared between COPD and non-COPD patients

Management information
Registered date
2016 Year 03 Month 31 Day
Last modified on
2016 Year 04 Month 05 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000025036